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ABSTRACT. Glutathione S-transferases (GSTs) are a family of phase 
II metabolizing enzymes involved in carcinogen detoxification and the 
metabolism of various bioactive compounds. Several genes that code 
for these enzymes are polymorphic in an ethnicity-dependent manner, 
with particular genotypes previously associated with an increased 
risk of breast cancer. The purpose of this study was to determine the 
frequencies of polymorphisms in the genes GSTM1, GSTT1, GSTP1, 
and GSTM3 and to investigate whether an association exists between 
these genes and breast cancer risk in subjects from northeastern 
Mexico. Genotypes were determined for 243 women with histologically 
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confirmed breast cancer and 118 control subjects. Gene polymorphisms 
were analyzed using a DNA microarray. We found an increased breast 
cancer risk associated with the GSTM1 gene deletion polymorphism 
(OR = 2.19; 95%CI = 1.50-3.21; P = 0.001). No associations between 
the GSTT1, GSTP1, and GSTM3 genotypes and neoplasia risk were 
observed. In conclusion, we determined the genotype distribution of 
GST polymorphisms in control subjects and breast cancer patients 
from northeastern Mexico. The GSTM1 null genotype was associated 
with breast cancer risk. Our findings may be used to individualize 
breast cancer screening and therapeutic intervention in our population, 
which displays ethnic characteristics that differentiate it from other 
populations in Mexico.
Key words: Breast cancer; Ethnicity; Glutathione S-transferases; 
Northeastern Mexico; Polymorphisms
INTRODUCTION
Breast cancer is the most frequently diagnosed malignancy and the leading cause 
of cancer death in females in both developed and developing countries (Jemal et al., 2011). 
Although the mechanism of breast carcinogenesis is not fully understood, it is clear that both 
genetic and environmental factors play a role in this disease. Up to 5% of all breast cancers 
arise from germ-line mutations in high-penetrance breast cancer susceptibility genes such as 
BRCA1 and BRCA2. Therefore, the interaction between polymorphic, low-penetrance genes, 
and lifestyle or environmental risk factors likely accounts for a much higher proportion of 
breast cancer cases (Sarmanová et al., 2004).
Low-penetrance genes can participate in the detoxification of environmental car-
cinogens, steroid hormone metabolism, and DNA damage repair pathways (Mitrunen and 
Hirvonen, 2003). Glutathione S-transferases (GSTs) are a family of phase II metabolizing 
enzymes involved in carcinogen detoxification and the metabolism of various bioactive 
compounds (Coles and Kadlubar, 2003). Functional polymorphisms in GSTM1, GSTT1, and 
GSTP1 have been investigated for their associations with breast cancer in a large number of 
studies (Egan et al., 2004; Syamala et al., 2008; Van Emburgh et al., 2008; Saxena et al., 2009; 
Ramalhinho et al., 2011; Reding et al., 2012; Sohail et al., 2013). In contrast, studies analyzing 
the relationship between GSTM3 and breast cancer are limited (Mitrunen et al., 2001). Identifi-
cation of inter-individual variability in GST polymorphisms may be useful for individualizing 
breast cancer screening and therapeutic intervention.
Most studies previously were carried out in Caucasians, African-Americans, and 
Asians. In Mexico, only one related study has been carried out, in which subjects in the 
country’s central zone were analyzed (Martínez-Ramírez et al., 2013). Thus, the purpose 
of this study was to investigate the genotypic and allelic frequencies of polymorphisms in 
GSTM1, GSTT1, GSTP1, and GSTM3 to determine whether an association exists between 
polymorphisms in these genes and the risk of breast cancer in subjects from northeastern 
Mexico.
6467GSTs and breast cancer in northeastern Mexico
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 14 (2): 6465-6471 (2015)
MATERIAL AND METHODS
Biological samples
The patient population and methods have been described in detail in a previous report 
(Alcazar-González et al., 2013). The case subjects included 243 women with histologically 
confirmed breast cancer who received chemotherapy at the University Cancer Center of the 
University Hospital “Dr José E González” of the Autonomous University of Nuevo Leon and 
the Hospital of Specialities number 25 of the Mexican Institute of Social Security, both located 
in Monterrey, Nuevo León, Mexico. Both are reference centers for breast cancer patients from 
throughout the northeastern area of Mexico, including the states of Zacatecas, San Luis Potosí, 
Tamaulipas, Coahuila, and Nuevo León. A total of 118 controls with no previous history of 
any type of cancer or other vital disease were also studied. This study conformed to the Dec-
laration of Helsinki, was approved by the local ethics committee (registration HU BI10-002), 
and all participants provided informed written consent.
Genotyping
Genomic DNA was obtained from peripheral blood samples either using the QIAamp 
DNA Blood Mini Kit (Qiagen, Hilden, Germany) following the manufacturer protocol or using 
TSNT lysis buffer (1% Triton, 1% sodium dodecyl sulfate, 100 mM NaCl, 10 mM Tris-HCl, 
pH 8.0, and 1 mM EDTA) followed by phenol-chloroform extraction and ethanol precipitation.
Analysis of gene polymorphisms was performed using the PHARMAchip® DNA mi-
croarray following manufacturer protocols (Progenika Biopharma SA, Derio, Spain). Deletion 
polymorphisms in GSTM1 and GSTT1 and a base transition polymorphism at codon 105 (Ile/
Val) in GSTP1 were analyzed. In the GSTM3 gene, the GSTM3*A wild-type and GSTM3*B 
variant allele, which differed by a deletion of 3 base pairs in intron 6, were analyzed.
Statistical analysis
To identify significant differences in polymorphism frequencies between case and 
control groups, allele and genotype frequencies were compared statistically using the R x C 
contingency-table exact test. Hardy-Weinberg equilibrium (HWE) for GSTP1 and GSTM3 
was estimated using the Chi-square test. HWE was not evaluated for GSTM1 and GSTT1 
because the genotyping method did not distinguish heterozygous and homozygous genotypes. 
The data were input to SPSS, version 22.0 (SPSS Inc., Chicago, IL, USA) for handling and 
further statistical analyses. ORs and 95%CI were calculated to determine significant associa-
tions using the Epi Info program (version 7.1.3, CDC, Atlanta, GA, USA). In all analyses, a 
significance level of 0.05 was adopted.
RESULTS
Genotypes and allele distributions of GSTM1, GSTT1, GSTP1, and GSTM3 polymor-
phisms in cases and controls are summarized in Table 1. Thirty-four (30.1%) of the con-
trol subjects had the GSTM1 null genotype. The observed frequency of the null genotype in 
breast cancer patients was 48.5%. The GSTM1 null genotype was associated with a 2.19-fold 
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(95%CI = 1.50-3.21) increase in the risk of developing breast cancer. This association was 
statistically significant (P = 0.001).
Gene Frequencies Cases [Na (%)] Controls [Na (%)] P valueb
GSTM1 Genotype   
 Present  124 (51.5)    79 (69.9) 0.001
 Null  117 (48.5)    34 (30.1) 
 Total 241 (100) 113 (100) 
    
GSTT1 Genotype   
 Present  211 (86.8)    92 (80.9) 0.156
 Null    32 (13.2)    22 (19.1) 
 Total 243 (100) 114 (100) 
    
GSTP1 Genotype   
 Ile/Ile    58 (24.0)    35 (29.7) 0.301
 Ile/Val 105 (43.4)    53 (44.9) 
 Val/Val    79 (32.6)    30 (25.4) 
 Total 242 (100) 118 (100) 
 c2 3.82c 1.18d 
 Allele   
 Ile   0.4570   0.5212 
 Val   0.5430   0.4788 
    
GSTM3 Genotype   
 *A/*A  198 (83.9)  102 (87.2) 0.329
 *A/*B    34 (14.4)    15 (12.8) 
 *B/*B    4 (1.7)    0 (0.0) 
 Total 236 (100) 117 (100) 
 c2 2.93d 0.54d 
 Allele   
 *A   0.9110   0.9359 
 *B   0.0890   0.0641
c2 = Hardy-Weinberg equilibrium. aNumbers may not sum to totals due to missing data. bR x C with 50,000 
simulations. cP = 0.05. dP > 0.05
Table 1. Genotype and allele frequencies of glutathione S-transferase (GST) genes polymorphisms in breast 
cancer patients and healthy controls from northeastern Mexico.
The GSTT1 null genotype was observed in 13.2 and 19.1% of cases and controls, 
respectively. In all, 43.4% of cases and 44.9% of controls were heterozygous and 32.6% of 
cases and 25.4% of controls were homozygous for the GSTP1 Ile105Val polymorphism. Fi-
nally, when the GSTM3 gene was analyzed, 14.4% of cases and 12.8% of controls carried the 
heterozygous *A/*B genotype, while 1.7% of cases and 0.0% of controls carried the homozy-
gous *B/*B genotype. The distribution of genotype frequencies of GSTP1 and GSTM3 were 
in HWE, with the exception of GSTP1 frequencies in breast cancer cases. No associations 
between GSTT1, GSTP1, and GSTM3 genotypes and breast cancer risk were observed.
DISCUSSION
Enzymes involved in carcinogen detoxification and metabolism of bioactive com-
pounds have been shown to be polymorphic in an ethnicity-dependent manner. In the pres-
ent study, genetic polymorphisms of GSTs were investigated in subjects from northeastern 
Mexico, and their possible association with breast cancer risk was evaluated.
The genotype distributions for GSTM1, GSTT1, and GSTP1 polymorphisms in control 
subjects were in agreement with the results of previous reports in Mexicans subjects (Pérez-
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Morales et al., 2011; Martínez-Rodríguez et al., 2013). The frequency of the GSTM1 null 
genotype found in this study was 30%, which is similar to the values observed in Asians and 
African Americans (~27%), but not similar to the value in Caucasians (~50%). The frequen-
cies of the Ile/Ile (29%) and Val/Val (25%) genotypes of GSTP1 found in this study were more 
similar to those in African Americans (~29 and ~20%, respectively) that in Caucasians (~44 
and ~10%) and Asians (~49 and ~7%). The GSTT1 null genotype frequency (19%) was simi-
lar to that in most populations analyzed thus far (Egan et al., 2004; Syamala et al., 2008; Van 
Emburgh et al., 2008; Saxena et al., 2009; Ramalhinho et al., 2011; Reding et al., 2012; Sohail 
et al., 2013). Finally, we determined the frequencies of the GSTM3 genotypes in Mexican sub-
jects. Previous reports regarding GSTM3 genetic polymorphisms frequencies are very limited 
in the literature (Mitrunen et al., 2001).
A homozygous deletion (null genotype) of GSTM1 or GSTT1 was found to be associ-
ated with a lack of the corresponding enzyme activity. The presence of the substitution of iso-
leucine for valine results in reduced activity of the GSTP1 enzyme. Relatively little is known 
about the role of GSTM3 in the metabolism of carcinogenic compounds, but the GSTM3 *A 
and *B alleles may be expressed at different levels with different efficiencies in the metabo-
lism of harmful agents (Mitrunen et al., 2001). This may compromise an individual’s ability 
to deactivate carcinogens, thus increasing the risk of cancer (Mitrunen and Hirvonen, 2003). 
In the current study, only the GSTM1 null genotype was associated with breast cancer risk. 
We found no significant increase in breast cancer risk associated with the GSTT1, GSTP1, and 
GSTM3 genotypes.
A large number of studies have examined the relationship between GST polymor-
phisms and breast cancer risk. Overall, no clear pattern has emerged. Studies in which an 
association between individual or combined GST genotypes and breast cancer was observed 
were not confirmed by other studies and were refuted (Mitrunen et al., 2001; Egan et al., 2004; 
Syamala et al., 2008; Van Emburgh et al., 2008; Saxena et al., 2009; Ramalhinho et al., 2011; 
Reding et al., 2012; Sohail et al., 2013; also see for reviews and meta-analyses: Mitrunen and 
Hirvonen, 2003; Sergentanis and Economopoulos, 2010; Chen et al., 2011). The discrepancies 
among studies may be due to several factors, including differences in ethnicity, environmental 
exposure to carcinogens, and diet. Alternatively, these differences may be attributable to meth-
odological issues, such as the study design, sample size, and analysis method.
In the only previous related study carried out in Mexico, GSTP1 polymorphisms were 
associated with an increased breast cancer risk; no association was observed for GSTM1 and 
GSTT1 (Martínez-Ramírez et al., 2013). The differences between this study and our results are 
likely related to ethnicity and methodological factors.
The admixture among Amerindians, Europeans, and Africans resulted in Mestizos, 
who represents more than 90% of the Mexican population (Instituto Nacional de Estadísti-
ca y Geografía, 2010). However, the Mexican population exhibits high genetic variability. 
Rubi-Castellanos et al. (2009) analyzed the genetic data of 13 combined DNA index system-
short tandem repeats in subjects representing population samples from different regions of 
Mexico. They found significant genetic differentiation among Mestizos from different Mexi-
can regions, mainly between the North and the Central and South regions. Furthermore, they 
observed genetic heterogeneity or asymmetric admixture throughout Mexico, displaying an 
increasing North-to-South gradient of Amerindian ancestry, and vice versa regarding the Eu-
ropean component. Our study examined subjects from northeastern Mexico, whereas in the 
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previous study, subjects of the country’s central zone were analyzed. Thus, ethnic diversity 
may have contributed to the discrepancies observed between these studies.
However, the differences in results between both studies may be related to method-
ological issues. In our study, the genotype frequencies of GSTP1 deviated from the HWE in the 
case group (Table 1). Because other polymorphisms did not deviate from HWE, our sample set 
was appropriately ascertained (Wittke et al., 2005). Deviation from HWE may have resulted 
from random selection, likely because of sample size. Thus, an analysis of a larger sample size 
of our population may reveal an association between the GSTP1 genotype and breast cancer 
risk, which would coincide with the results of the other study carried out in Mexico.
In conclusion, we determined the genotype distribution of GSTM1, GSTT1, GSTP1, 
and GSTM3 polymorphisms in control subjects and breast cancer patients from northeastern 
Mexico. Only the GSTM1 null genotype was associated with breast cancer risk. Analysis of a 
larger sample, inclusion of matched controls, and the consideration of gene-environment in-
teractions could augment our understanding of the association between GSTs and breast cancer 
risk in our population.
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